88519-57-7 Usage
Description
W-13 is a naphthalenesulfonamide derivative that acts as a potent antagonist of calmodulin (IC50 = 22 μM) and is widely used to investigate Ca2+/calmodulin-regulated enzyme activities.
Chemical Properties
Beige Solid
Uses
Different sources of media describe the Uses of 88519-57-7 differently. You can refer to the following data:
1. W-13 is a naphthalenesulfonamide derivative that acts as a potent antagonist of calmodulin (IC50 = 22 μM) and is widely used to investigate Ca2+/calmodulin-regulated enzyme activities.
2. Calmodulin antagonist that binds to calmodulin and inhibits calcium-ion-calmodulin- regulated activities, including phosphodiesterase activation and myosin light chain kinase127, it is widely used to investigate Ca2+/calmodulin-regulated enzyme activities.
Biological Activity
Calmodulin antagonist (inhibits calmodulin activated PDE activity with an IC 50 of 68 μ M). Inhibits growth of tamoxifen-resistant breast cancer cells.
Biochem/physiol Actions
W-13 has also been shown to inhibit the transcytosis of IgA, recycling of transferrin and overall alter the endocytic pathway in Madin-Darby canine kidney cells.
Check Digit Verification of cas no
The CAS Registry Mumber 88519-57-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,5,1 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 88519-57:
(7*8)+(6*8)+(5*5)+(4*1)+(3*9)+(2*5)+(1*7)=177
177 % 10 = 7
So 88519-57-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H17ClN2O2S.ClH/c15-14-5-3-4-11-10-12(6-7-13(11)14)20(18,19)17-9-2-1-8-16;/h3-7,10,17H,1-2,8-9,16H2;1H
88519-57-7Relevant articles and documents
Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
-
, (2008/06/13)
A method of regulating phosphorylation of proteins involved in controlling processing or function of key proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques associated with Alzheimer disease comprising introducing an effective amount of a kinase modulator or phosphatase modulator, the modulator capable of increasing or decreasing the rate of proteolytic processing, or modulating the function, of said key proteins.